HS-10365

This study aims to evaluate the material balance and metabolic pathways of [14C]HS-10365 after a single oral dose in healthy Chinese male subjects, reveal the overall pharmacokinetic characteristics of HS-10365 in humans, and provide a reference for the rational use of drugs. Main objectives: 1. Quantitatively analyze the total radioactivity in the excreta of subjects after oral administration of [14C]HS-10365, and obtain data on human radioactive excretion rate and main excretion pathways. 2. Obtain the radioactive metabolite spectrum of plasma, urine and feces of subjects after oral administration of [14C]HS-10365, identify the main metabolites, determine the metabolic pathways and elimination pathways. 3. Quantitatively analyze the total radioactivity in whole blood and plasma of subjects after a single oral administration of [14C]HS-10365, obtain the pharmacokinetic parameters of total radioactivity in whole blood and plasma, and investigate the distribution of total radioactivity in whole blood and plasma. Secondary objectives: 1. To quantitatively analyze the concentrations of HS-10365 and metabolites (if applicable) in plasma using a validated LC-MS/MS method and obtain the pharmacokinetic parameters of HS-10365 and metabolites (if applicable) in plasma. 2. To observe the safety of subjects after a single dose of [14C]HS-10365.